Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

BACKGROUND & AIMS: Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Kate D., Chapman, Roger W., Keshav, Satish, Montano-Loza, Aldo J., Mason, Andrew L., Kremer, Andreas E., Vetter, Marcel, de Krijger, Manon, Ponsioen, Cyriel Y., Trivedi, Palak, Hirschfield, Gideon, Schramm, Christoph, Liu, Chung Heng, Bowlus, Christopher L., Estes, Derek J., Pratt, Daniel, Hedin, Charlotte, Bergquist, Annika, de Vries, Annemarie C., van der Woude, C. Janneke, Yu, Lei, Assis, David N., Boyer, James, Ytting, Henriette, Hallibasic, Emina, Trauner, Michael, Marschall, Hanns-Ulrich, Daretti, Luigi M., Marzioni, Marco, Yimam, Kidist K., Perin, Nicola, Floreani, Annarosa, Beretta-Piccoli, Benedetta Terziroli, Rogers, Jennifer K., Levy, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders for the American Gastroenterological Association 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941216/
https://www.ncbi.nlm.nih.gov/pubmed/31100458
http://dx.doi.org/10.1016/j.cgh.2019.05.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941216/
https://www.ncbi.nlm.nih.gov/pubmed/31100458
http://dx.doi.org/10.1016/j.cgh.2019.05.013

Ejemplares similares